To use Aduhelm or not to use Aduhelm- that is the question…now what is the evidence? Part 2
Sep 20th, 2022 by Vizient
Dr. Mandy Leonard, Senior Director of Drug Use Policy and Formulary Management at Cleveland Clinic and Steven Lucio, Senior Principal in Pharmacy Solutions at Vizient discuss their insights on the approval, role, and coverage of Aducanumab, the first drug in a new class approved for Alzheimer’s by the FDA’s accelerated approval process.
Mandy Leonard, PharmD, BCPS
Senior Director of Drug Use Policy and Formulary Management
Steven Lucio, PharmD, BCPS
Senior Principal in Pharmacy Solutions
Gretchen Brummel, PharmD, BCPS
Pharmacy Executive Director
Vizient Center for Pharmacy Practice Excellence
[00:47 -3:06] Other factors driving aducanumab formulary decision making
[03:07-6:35] How CMS is managing this medication
[06:36-9:04] What should patients and families know about this medication?
[09:05-12:33] What frontline pharmacists should know about this medication
Links | Resources: